Related Experiment Videos
[Clinical studies of T-1982 (cefbuperazone) in pediatric field]
Insights
T-1982, a new cephamycin antibiotic, demonstrated high efficacy in treating various infections, including pneumonia. Clinical trials showed a 94.4% overall efficacy rate with no observed adverse reactions in patients.
Area of Science:
- Pharmacology
- Infectious Diseases
- Clinical Medicine
Background:
- Cephamycin antibiotics represent a crucial class of antimicrobial agents.
- The development of novel antibiotics is essential for combating evolving bacterial resistance.
- T-1982 (cefbuperazone) is a recently developed cephamycin with potential therapeutic applications.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of T-1982 (cefbuperazone) in patients with bacterial infections.
- To determine the appropriate dosage and treatment duration for T-1982 (cefbuperazone).
Main Methods:
- A clinical study involving 18 patients with various infections, including pneumonia, purulent tonsillitis, acute bronchitis, cellulitis, and urinary tract infections.
- Intravenous administration of T-1982 (cefbuperazone) at daily doses ranging from 27.4 to 100.2 mg/kg, divided into 3-4 doses.
- Treatment duration varied from 3 to 6.7 days.
Main Results:
- An overall efficacy rate of 94.4% was observed across all treated patients.
- No adverse reactions were reported during the study period.
- Minor laboratory abnormalities included liver dysfunction (4.8%), eosinophilia (9.5%), and anemia (4.8%) in a small number of patients.
Conclusions:
- T-1982 (cefbuperazone) exhibits significant efficacy in treating a range of bacterial infections.
- The antibiotic appears to be well-tolerated, with a favorable safety profile.
- Further investigation into T-1982 (cefbuperazone) is warranted for its potential role in clinical practice.
Abstract:
T-1982 (cefbuperazone) is a newly developed cephamycin. Clinical studies on this drug were carried out and the results were as follows: Eighteen patients (pneumonia 13, purulent tonsillitis 1, acute bronchitis 1, cellulitis 1, urinary tract infection 2) were treated intravenously with daily 27.4-100.2 mg/kg of T-1982 in 3-4 divided dose for 3-6.7 days. The overall efficacy rate was 94.4%. No adverse reactions were observed. Abnormal laboratory data noted were liver dysfunction in 1 case (4.8%), eosinophilia in 2 cases (9.5%), and anemia in 1 case (4.8%).